Outlook for Itchy Prurigo Nodularis Continues to Improve With IL-31 Antagonist

(MedPage Today) -- NEW ORLEANS -- An investigational antibody targeting interleukin (IL)-31 in prurigo nodularis significantly reduced itch, skin lesions, and sleep disturbance in a phase III trial. More than half of patients treated with nemolizumab...
Source: MedPage Today Dermatology - Category: Dermatology Source Type: news